Relias is set to expand its learning offerings by incorporating assessment-based virtual reality (VR) through its acquisition ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and development, particularly in clinical trials. The good news is that ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a subgroup of breast cancer patients, but not the overall study population.